Group 4 Created with Sketch.
Your changes have been saved

Shaping the Possibilities for Patients Everywhere: A Conversation with Zymeworks' Tony Polverino, PhD

Share
station description Updates from all Oncology & Hematology Disciplines and Sub-specialties.
The Onco'Zine Brief
Duration: 46:52
In this edition of The Onco’Zine Brief Peter Hofland, Ph.D talks with Tony Polverino, PhD. In September 2918 Polverino joined Zymeworks, a clinical-stage, biopharmaceutical company developing next-generation multifunctional biotherapeutics. He currently serves as the company's Executive Vice Preside
Snippets are a new way to share audio!
You can clip a small part of any file to share, add to playlist, and transcribe automatically. Just click the to create your snippet!
Snippets: Clips of Shaping the Possibilities for Patients Everywhere: A Conversation with Zymeworks' Tony Polverino, PhD that people like
There are currently no snippets from Shaping the Possibilities for Patients Everywhere: A Conversation with Zymeworks' Tony Polverino, PhD.
Snippets are an easy way to highlight your favorite soundbite from any piece of audio and share with friends, or make a trailer for The Onco'Zine Brief
Playlists that Shaping the Possibilities for Patients Everywhere: A Conversation with Zymeworks' Tony Polverino, PhD appears on.
There are currently no playlists containing this audio.
Add this audio track to one of your playlists
Add to Playlist
Up Next
Full Description
Back to Top
In this edition of The Onco’Zine Brief Peter Hofland, Ph.D talks with Tony Polverino, PhD. In September 2918 Polverino joined Zymeworks, a clinical-stage, biopharmaceutical company developing next-generation multifunctional biotherapeutics. He currently serves as the company's Executive Vice President of Early Development and Chief Scientific Officer. Prior to joining Zymeworks, from 2015 until 2018, Polverino was at Kite Pharma, which was acquired by Gilead Sciences in 2017. Zymeworks’ lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody that has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2-amplified biliary tract cancer (HERIZON-BTC-01)[1][2][3[[4] as well as several Phase 2 clinical trials for HER2-expressing gastroesophageal and breast cancers. Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas.In our program today Hofland asks Polverino about his work in oncology, his work before joining Zymeworks, and the work he and his co-workers are doing at Zymeworks.About The Onco'Zine BriefThe Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: https://www.patreon.com/theoncozinebriefFor more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.comTo sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.Reference[1] A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers - NCT04466891[2] A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer - NCT04224272[3] A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer - NCT03929666[4] A Dose-Finding Study of ZW49 in Patients With HER2-Positive Cancers - NCT03821233
Up Next
Add to playlist
New playlist

Embed

COPY
Embed Options
Create Playlist
Select the Station you want to upload this audio to
Station
0 / 140
0 / 2000
Playlist Icon Image:
(.jpg, .png, min size 500x500px)
Privacy
Subscribers
Your
voice
matters.
Discover & Listen to the world’s largest free collection of audio
Password reset

Enter your email address that you used to register. We'll send you an email with your username and a link to reset your password.



If you still need help, contact Vurbl Support
Password reset sent

You have been sent instructions on resetting you password to the email associated with your account. Please check your email and signing in again.


Back to Sign In
If you still need help, contact Vurbl Support
Your
voice
matters.
Discover & Listen to the world’s largest free collection of audio
Reset password

Please enter your new password below.



If you still need help, contact Vurbl Support
Your voice matters.
Discover & Listen to the world’s largest free collection of audio
Verify Email

Enter your email address that you used to register. We'll send you an email with a link to verify your email.



Cancel
Delete Profile
Are you sure? We will miss you :'(
Delete
Delete Audio
Are you sure?
Delete
Delete Playlist
Are you sure you want to delete this playlist?
Delete
Notifications
You must be signed in to view
your notifications. Please sign in
Edit Snippet
0 / 140
0 / 140

Tag a Station

Type station name to add additional tags
*Station owners will be notified when you tag them
Open this link in the Vurbl Mobile App for the full Vurbl experience.
Open in Vurbl mobile app
Continue to Vurbl website